Navigation Links
EMA Starts Formal Review of Glybera(R) Dossier
Date:1/25/2010

AMSTERDAM, The Netherlands, January 25 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, has reached another important milestone in the official marketing authorisation process for its lead product Glybera(R), AMT's proprietary product for lipoprotein lipase deficiency (LPLD). The submission of the Glybera(R) Marketing Authorisation Application (MAA), announced earlier, has cleared the validation stage with The European Medicines Agency (EMA, formerly known as EMEA). The EMA will now commence its formal review of Glybera(R).

AMT has concluded two clinical studies for LPLD, in Europe and Canada, and long term follow-up from both of these is ongoing, as is a third clinical study in Canada. In these three studies Glybera(R) has shown a sizeable decrease in the incidence of pancreatitis, or acute inflammation of the pancreas, the most debilitating complication of LPLD. In addition, these studies indicate that Glybera(R) has an excellent safety profile.

"The acceptance of the Glybera(R) dossier by EMA is a significant step towards marketing approval for Glybera(R). Moreover, it demonstrates AMT's development capability. A future approval of the MAA for Glybera would fully validate our gene therapy approach and our adeno-associated viral (AAV) vector delivery platform. We believe this step offers hope to many patients, as gene therapy may become the therapeutic approach of choice for inherited disorders" said Jorn Aldag, Chief Executive Officer of AMT.

The EMA formal review will be conducted via the centralised procedure, which is the standard route for all advanced therapies. During 2010, AMT expects to provide further updates on the r
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
2. AMT Starts Preregistration Trial for Glybera(TM)
3. Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
4. BioCis Pharma Starts Phase IIa Trial in Psoriasis
5. The Pittsburgh Life Sciences Greenhouse Starts 2009 With Investment Momentum
6. China Sky One Medical, Inc. Starts Production at Newly Acquired Facility and Reaffirms Guidance
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
11. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
(Date:7/24/2014)... -- A novel combination of microscopy and data processing ... Ridge National Laboratory an unprecedented look at the surface ... electrochemical properties. , The research team led by ... of a perovskite manganite, a complex material that exhibits ... understand surface behavior could benefit researchers who are interested ...
(Date:7/24/2014)... July 24, 2014  ECC West Africa, LLC (ECC) ... with University College Hospital (UCH) Ibadan Board of ... to finance, design, construct, and operate and maintain a ... . Under the first of the 4-phase project, ... and funding applications. UCH Ibadan intends to finance and ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3ORNL study reveals new characteristics of complex oxide surfaces 2ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... therapeutics, today announced its financial and operational,results ... ended May 31st, 2008., "Throughout the ... moving,ARIUS, anti-cancer antibodies towards human clinical trial. ...
... , The white blood cells in our body combat ... leukemia, the formation of white blood cells is disturbed: ... multiply out of control without fully maturing. This process ... more susceptible to infections. T-ALL, a particular form of ...
... electronic device is an important step toward helping astronomers ... universe. This invisible light makes up 98% of the ... insights into the earliest stages of star and galaxy ... new circuit, developed by physicsts at Rutgers University, NASA,s ...
Cached Biology Technology:ARIUS announces second quarter fiscal 2008 financial results 2ARIUS announces second quarter fiscal 2008 financial results 3ARIUS announces second quarter fiscal 2008 financial results 4ARIUS announces second quarter fiscal 2008 financial results 5ARIUS announces second quarter fiscal 2008 financial results 6ARIUS announces second quarter fiscal 2008 financial results 7ARIUS announces second quarter fiscal 2008 financial results 8ARIUS announces second quarter fiscal 2008 financial results 9ARIUS announces second quarter fiscal 2008 financial results 10ARIUS announces second quarter fiscal 2008 financial results 11ARIUS announces second quarter fiscal 2008 financial results 12ARIUS announces second quarter fiscal 2008 financial results 13ARIUS announces second quarter fiscal 2008 financial results 14ARIUS announces second quarter fiscal 2008 financial results 15Not the protein, but its location in the cell, determines the onset of leukemia 2Nano-sized electronic circuit promises bright view of early universe 2Nano-sized electronic circuit promises bright view of early universe 3
(Date:7/25/2014)... puberty is influenced by ,imprinted genes,a subset of genes whose ... This is the first evidence that imprinted genes can control ... study were published today in the journal Nature . ... a marker for the timing of puberty in females. ... girls, is an inherited trait, and is linked to breast ...
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/25/2014)... July 25, 2014 Biometrics industry ... turning to digital technology for online & commerce payments ... Inc. (NASDAQ: GOOG ), LifeLock Inc. (NYSE: ... V ), Apple Inc. (NASDAQ: AAPL ) ... (OTCQB: NXTD) a biometric authentication company focused on the ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... the AAAS Symposium, "Emerging Threats and Research Challenges ... 10:30. William Laurance, senior staff scientist ... moderator, recently co-organized a major event, "Debating the ... Natural History in Washington, which was featured in ...
... used in biomedicine and engineering likely won,t cause unexpected ... presented today. The result should allay fears that cells ... finest silica nanomaterials in industrial or commercial applications. ... size doesn,t matter, by using total surface area as ...
... simple, chemical materials model may lead to a better ... according to a Penn State researcher. "Cells are interesting ... the cytoplasm, and while it is thought to be ... how this organization is achieved," said Christine Keating, associate ...
Cached Biology News:AAAS Symposium: Emerging threats to tropical, temperate and ocean ecosystems 2Nanoparticle toxicity doesn't get wacky at the smallest sizes 2Nanoparticle toxicity doesn't get wacky at the smallest sizes 3Artificial cells, simple model for complex structure 2Artificial cells, simple model for complex structure 3
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Human VEGF-D Biotinylated MAb (Clone 78923)...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Biology Products: